【レポートの概要（一部）】
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE ANALYSIS
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Biologics – Market size and forecast 2018-2023
• Non-biologics – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
• PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Strategic focus on alliances, partnerships, and M&A
• Emergence of combination therapies and novel targets
• Rising demand for genetic tests and protein biomarkers
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services Inc.
• Novartis AG
• Takeda Pharmaceutical Co. Ltd.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Recent mega-mergers in pharmaceuticals
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Some of the first-in-class orphan drugs approved by the US FDA during 2017-2018
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Some of the late-stage orphan drugs
Exhibit 20: Product – Market share 2018-2023 (%)
Exhibit 21: Comparison by product
Exhibit 22: Biologics – Market size and forecast 2018-2023 ($ billions)
Exhibit 23: Number of new or expanded indications approved for novel orphan biologics to the number of rare and non-rare diseases from the US FDA January 2013-June 2019
Exhibit 24: Promising regenerative orphan drugs pricing plans
Exhibit 25: Biologics – Year-over-year growth 2019-2023 (%)
Exhibit 26: Non-biologics – Market size and forecast 2018-2023 ($ billions)
Exhibit 27: Non-biologics – Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America – Market size and forecast 2018-2023 ($ billions)
Exhibit 33: Number of orphan drug approvals in US 2014-2018
Exhibit 34: US FDA orphan drug marketing approvals in major therapeutic areas 2008-2017
Exhibit 35: List of expensive orphan drugs launched in US
Exhibit 36: Leading vendors and their product sales in US 2018.
Exhibit 37: Status of BTD, PR, and ODD for novel drugs 2013-2017
Exhibit 38: RMAT designation requests by product type 2018
Exhibit 39: North America – Year-over-year growth 2019-2023 (%)
Exhibit 40: Europe – Market size and forecast 2018-2023 ($ billions)
Exhibit 41: Orphan drug approvals in Europe during 2010-2018
Exhibit 42: Applications for ODD in EU 2005-2018
Exhibit 43: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 44: Asia – Market size and forecast 2018-2023 ($ billions)
Exhibit 45: Orphan drugs eligible for reimbursable under China’s state health insurance schemes
Exhibit 46: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 47: ROW – Market size and forecast 2018-2023 ($ billions)
Exhibit 48: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 49: Key leading countries
Exhibit 50: Market opportunity
Exhibit 51: List of promising drugs approved in US, Japan, and EU 2017-2019
Exhibit 52: Number of orphan drugs approved in US, EU, and Japan 2017 and 2018
Exhibit 53: Percentage of orphan and non-orphan drugs approved by the US FDA 2018
Exhibit 54: Incidence rate of rare diseases per year in US
Exhibit 55: Prevalence of rare diseases 2018 (millions)
Exhibit 56: Orphan drugs regulatory framework and incentives in key leading regions or countries
Exhibit 57: Impact of drivers and challenges
Exhibit 58: Several major M&A in the market
Exhibit 59: Expansion of combination therapies research areas of ICI approved drugs
Exhibit 60: Ongoing immunotherapy combinations studies with co-inhibitory molecules
Exhibit 61: Ongoing immunotherapy combinations studies with co-stimulatory molecules
Exhibit 62: Vendor landscape
Exhibit 63: Landscape disruption
Exhibit 64: Vendors covered
Exhibit 65: Vendor classification
Exhibit 66: Market positioning of vendors
Exhibit 67: Bristol-Myers Squibb Co. – Vendor overview
Exhibit 68: Bristol-Myers Squibb Co. – Business segments
Exhibit 69: Bristol-Myers Squibb Co. – Organizational developments
Exhibit 70: Bristol-Myers Squibb Co. – Geographic focus
Exhibit 71: Bristol-Myers Squibb Co. – Key offerings
Exhibit 72: Bristol-Myers Squibb Co. – Key customers
Exhibit 73: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 74: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 75: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 76: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 77: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 78: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 79: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 80: Johnson & Johnson Services Inc. – Vendor overview
Exhibit 81: Johnson & Johnson Services Inc. – Business segments
Exhibit 82: Johnson & Johnson Services Inc. – Organizational developments
Exhibit 83: Johnson & Johnson Services Inc. – Geographic focus
Exhibit 84: Johnson & Johnson Services Inc. – Segment focus
Exhibit 85: Johnson & Johnson Services Inc. – Key offerings
Exhibit 86: Johnson & Johnson Services Inc. – Key customers
Exhibit 87: Novartis AG – Vendor overview
Exhibit 88: Novartis AG – Business segments
Exhibit 89: Novartis AG – Organizational developments
Exhibit 90: Novartis AG – Geographic focus
Exhibit 91: Novartis AG – Segment focus
Exhibit 92: Novartis AG – Key offerings
Exhibit 93: Novartis AG – Key customers
Exhibit 94: Takeda Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 95: Takeda Pharmaceutical Co. Ltd. – Business segments
Exhibit 96: Takeda Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 97: Takeda Pharmaceutical Co. Ltd. – Geographic focus
Exhibit 98: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibit 99: Takeda Pharmaceutical Co. Ltd. – Key customers
Exhibit 100: Validation techniques employed for market sizing
Exhibit 101: Definition of market positioning of vendors
【レポート販売概要】
■ タイトル：オーファンドラッグ（希少疾患治療薬）の世界市場2019-2023■ 英文：Orphan Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023
■ 発行日：2019年8月26日
■ 調査会社：Technavio
■ 商品コード：IRTNTR31893
■ 調査対象地域：グローバル、アジア太平洋、ヨーロッパ、北米、その他
- ライドシェアの世界市場予測（～2025年）“Growing need for personal mobility in the wake of rising urbanization and fall in car ownership are expected to fuel the demand for ride sharing”The ride sharing market is estimated to be USD 61.3 billion in 2018 and is projected to reach USD 218.0 billion by 2025, at a CAGR of 19.87%. The growing need for personal mobility in the wake of rising urbanization and fall in car ownership is driving t …
- 世界のプロジェクトポートフォリオ管理市場：コンポーネント別（ソリューション＆サービス）、組織規模別、展開モード別、業種別（エネルギー＆ユーティリティ、政府＆防衛、製造、ヘルスケア＆ライフサイエンス）、地域別Growing demand for cloud-based PPM solution to gain a birds view on project operations and resource management are expected to drive the growth of the PPM market The global Project Portfolio Management (PPM) market size is expected to grow from USD 4.0 billion in 2019 to USD 5.6 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 6.9% during the forecast period. The PPM market is driven by …
- 体外受精（IVF）のイギリス市場：サイクルタイプ別、エンドユーザー別The UK IVF market was valued at $514 million in 2018 and is estimated to reach $928 million by 2026, registering a CAGR of 7.6% during the analysis period. In-vitro-Fertilization (IVF) is a common artificial infertility treatment performed in the laboratory. The treatment involves removing an ova (egg or eggs) or ovum from the ovaries and allowing sperm to fertilize them in a laboratory dish. It i …
- 心肺用自己輸血装置の世界市場2016-2020About the Cardiopulmonary Autotransfusion Systems Market Autotransfusion involves the collection of blood before surgeries and its transfusion during cardiac operations. This procedure is processed in autotransfusion systems that help minimize blood loss by collecting and filtering the RBCs, and reinfusing the blood into an individual. Autotransfusion is an autologous technology involving the retr …
- LED照明の世界市場予測（～2022）：設置種類別、最終用途別、製品種類別（ランプ＆照明器具）、地域別“LED lighting market expected to grow at a high rate between 2016 and 2022” The global LED lighting market is expected to be valued at USD 92.40 billion by 2022 and is expected to witness a shipment of 14.01 billion units by 2022, at a CAGR of 13.66% and 21.23%, respectively, between 2016 and 2022. The increasing consumer demand for energy-efficient lighting systems, reduction in prices of LEDs, a …
- NFCトランザクション（支払処理）の世界市場About NFC Transaction NFC is a standard short-range connectivity, which uses high frequency wireless communication technology for peer-to-peer communication between two devices. End-users can use this technology to transfer data from one devices to another. NFC technology has revolutionized the ways in which people access, use data and information. NFC-enabled devices can be used for mobile paymen …
- 強化型ビジョンシステム（視覚装置）の世界市場予測（～2021）：赤外線、合成ビジョンシステム、GPS、ミリ波レーダーThe enhanced vision systems market is expected to grow from USD 202.7 Million in 2016 to USD 250.4 Million by 2021, at a CAGR of 4.32% during the forecast period. Aircraft safety, situational awareness, and reliable operations at low visibility are factors driving the growth of the enhanced vision systems market. Key players operating in the enhanced vision systems market are Honeywell Internation …
- 世界のサプライチェーン分析：LCDテレビ市場The worldwide LCD TV industry has entered the maturity phase, with shipments slowing down in recent years. However, bolstered by the 2014 FIFA World Cup, global LCD TV sales reached around 208 million units in 2014, up 4.2% year on year. This report profiles the worldwide and Taiwanese LCD TV markets, investigates into development trends of different products, including 3D TV, smart TV, and 4K TV, …
- 世界の軍事航空MRO（保守、修理、点検）市場（2014-2024）Summary The Global Military Aviation MRO Market 2014-2024 Report published by Strategic Defence Intelligence, provides readers with a detailed analysis of both historic and forecast global industry values, factors influencing demand, the challenges faced by industry participants, analysis of industry leading companies, and key news. Key Findings - The global military aviation MRO market is expecte …
- 世界のタンタルおよびニオブ(コロンビウム)市場：市場規模、動向、メーカー動向Scope The report presents a thorough study of tantalum and niobium (columbium), covering both global and regional markets It aims to give a proper picture of the market, as well as its trends, perspectives and opportunities Comprehensive data showing tantalum and niobium (columbium) production, consumption, trade statistics and prices are provided (both nationwide and worldwide) Each country’s mar …
- めまい(Vertigo)：世界の治験レビュー2014年下半期版Vertigo Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Vertigo Global Clinical Trials Review, H2, 2014" provides data on the Vertigo clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Vertigo. It includes an overview of the trial numbers and their recruitment status as per the site of trial conductio …
- ジオフェンシングの世界市場予測（～2022年）“The geofencing market is expected to grow at a Compound Annual Growth Rate (CAGR) of 27.5%, due to the increase in the number of connected devices, emergence of smartphones, and increasing social networking trends.”The global geofencing market is expected to grow from USD 542.7 million in 2017 to USD 1,825.3 million by 2022, at a CAGR of 27.5%. Technological advancements, rise in the use of spati …
- 世界の重曹市場2015The Global Sodium Bicarbonate Industry Report 2015 is a professional and in-depth study on the current state of the Sodium Bicarbonate industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Sodium Bicarbonate market analysis is provided for the international markets including development trends, competiti …
- 世界におけるアレルギー血液検査デバイスの製品パイプライン動向2015Allergy Blood Tests - Pipeline Review, 2015 Summary GlobalData's Medical Devices sector report, “Allergy Blood Tests - Pipeline Review, 2015" provides an overview of Allergy Blood Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players invol …
- Hyperparathyroidism：グローバル臨床試験レビューH2, 2013Hyperparathyroidism Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Hyperparathyroidism Global Clinical Trials Review, H2, 2013" provides data on the Hyperparathyroidism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperparathyroidism. It includes an overview of the trial numbers and their recru …
